Helsinn To Present At The 33rd Annual J.P. Morgan Healthcare Conference (January 12-15, 2015)
SOURCE Helsinn Group
LUGANO, Switzerland, January 12, 2015 /PRNewswire/ --
Helsinn, the Swiss Group focused on building quality cancer care, is pleased to announce that Riccardo Braglia, Helsinn's Chief Executive Officer, is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference 2015, Hotel Westin, San Francisco, California. His presentation, including an overview of the Helsinn Group and its key activities as well as programs, will take place on Wednesday, 14 January, 2015 at 10:00am PST, in room Elizabethan D.
About the Helsinn Group
Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the United States and a representative office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.
Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn's products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers. For further information on Helsinn Group, please visit http://www.helsinn.com
For more information please contact:
Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
Tel: +41-91-985-21-21
info-hhc@helsinn.com
For media / external enquiries
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal /Laura Thornton
Tel: +44(0)203-709-5700
Helsinn@consilium-comms.com
Help employers find you! Check out all the jobs and post your resume.
LUGANO, Switzerland, January 12, 2015 /PRNewswire/ --
Helsinn, the Swiss Group focused on building quality cancer care, is pleased to announce that Riccardo Braglia, Helsinn's Chief Executive Officer, is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference 2015, Hotel Westin, San Francisco, California. His presentation, including an overview of the Helsinn Group and its key activities as well as programs, will take place on Wednesday, 14 January, 2015 at 10:00am PST, in room Elizabethan D.
About the Helsinn Group
Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the United States and a representative office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.
Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing preclinical and clinical studies and associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn's products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers. For further information on Helsinn Group, please visit http://www.helsinn.com
For more information please contact:
Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
Tel: +41-91-985-21-21
info-hhc@helsinn.com
For media / external enquiries
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal /Laura Thornton
Tel: +44(0)203-709-5700
Helsinn@consilium-comms.com
Help employers find you! Check out all the jobs and post your resume.